X4 Pharmaceuticals(XFOR) - 2020 Q4 - Annual Report
X4 Pharmaceuticals(XFOR)2021-03-19 20:49UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________ (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 ________________________________________________________________________________________ ...